NCT05753306 2026-04-08
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06050252 2026-04-03
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03965234 2026-03-17
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT05285358 2026-03-13
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
Phase 1 Recruiting
NCT04858009 2025-12-16
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
Phase 2 Recruiting
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06423326 2025-07-30
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04278287 2024-12-13
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT03731442 2018-12-12
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
ChineseAMS
Phase 3 Recruiting